The Global Epidemiological Transition in Cardiovascular Diseases: Unrecognised Impact of Endemic Infections on Peripheral Artery Disease

Paul A. Agius1,2,3 · Julia C. Cutts1,4 · Peige Song5,6 · Igor Rudan5 · Diana Rudan7 · Victor Aboyans8 · Mary M. McDermott9 · Michael H. Criqui10 · F. Gerald R. Fowkes5 · Freya J. I. Fowkes1,2,3

Received: 23 June 2022 / Accepted: 25 June 2022 / Published online: 16 July 2022
© The Author(s) 2022

Abstract
An epidemiological transition in the prevalence of peripheral artery disease (PAD) is taking place especially in low- and middle-income countries (LMICs) where an ageing population and adoption of western lifestyles are associated with an increase in PAD. We discuss the limited evidence which suggests that infection, potentially mediated by inflammation, may be a risk factor for PAD, and show by means of an ecological analysis that country-level prevalence of the major endemic infections of HIV, tuberculosis and malaria are associated with the prevalence of PAD. While further research is required, we propose that scientists and health authorities pay more attention to the interplay between communicable and non-communicable diseases, and we suggest that limiting the occurrence of endemic infections might have some effect on slowing the epidemiological transition in PAD.

Keywords Peripheral arterial disease · Malaria · Tuberculosis · HIV · Epidemiology

Abbreviations
CVDs Cardiovascular diseases
HICs High-income countries
LMIC Low- and middle-income countries
PAD Peripheral artery disease

1 Introduction
Cardiovascular diseases (CVDs) caused by atherosclerosis in major arteries consist primarily of three conditions: coronary heart disease, cerebrovascular disease, and lower extremity peripheral artery disease (PAD). PAD has been traditionally considered a disease of high-income countries (HICs), but in recent years, a global epidemiological transition has occurred, similar to that for coronary heart disease and stroke1. Between 2000 and 2010, the number...
of cases of PAD increased by 13.1% in HICs but by a much larger 28.7% in low- and middle-income countries (LMICs). In 2010, more than two-thirds (69.7%) of PAD cases were in LMICs, the majority in Southeast Asia and the Western Pacific [1]. Since 2010, this increasing trend has persisted, so that by 2015, 234 million people globally were living with PAD [2].
2 Do Endemic Infections Increase the Risk of PAD?

Infection is a possible contributor to the pathogenesis of atherosclerosis, including PAD [4]. In immuno-epidemiological studies, antibodies to a wide range of pathogens, for example, *Chlamydia pneumonia*, *Helicobacter pylori* and cytomegalovirus, have been associated with an increased risk of PAD [5]. Whether common endemic infections are associated with a population’s risk of acquiring PAD, particularly in LMICs, has not been studied. Globally, the commonest major endemic infections which affect large groups in a population and may have chronic effects are human immunodeficiency virus (HIV), tuberculosis, and malaria. Recently, the possible influence of the SARS-CoV-2 virus is of interest but, unless of prolonged duration, is unlikely to have a significant effect on the development over many years of chronic atherosclerotic disease.

An association between positive HIV status and incident PAD has been observed in clinical and epidemiological studies, mostly in HICs [6–8]. In a case control study, in the Netherlands of 540 HIV patients and 524 controls, PAD occurred in 0.6% of controls but in 2.6% of HIV patients (p < 0.01) [7], and the increased risk was independent of age and smoking. In a cohort of 91,953 US veterans, incident rates of PAD were higher among HIV + than uninfected veterans (11.9 v 9.9 per 1,000 person years) and were still 19% higher after risk factor adjustment. Comparable findings have been observed in China [8] and Burundi [9] and have likewise taken account of possible confounding variables such as cardiovascular risk factors and anti-retroviral therapy.

Tuberculosis may be involved in the pathogenesis of CVDs [10], but only one study has examined the association with PAD [11]. In this population-based cohort study in Taiwan of 14,350 tuberculosis patients and 28,700 non-tuberculosis subjects, the incidence of PAD over a 6-year follow-up was 5.4 vs 3.7 per 1000 patient years in the tuberculosis vs control cohorts. The hazard ratio adjusting for age, sex, co-morbidities and socio-economic status, was 3.9. Although the increased risk of PAD in tuberculosis patients was substantial, further studies are required. Nevertheless, pathogenic mechanisms occurring in tuberculosis and in infection more broadly, such as increased expression of pro-inflammatory cytokines and immune activation, could promote atherogenesis, making a causal association between tuberculosis and PAD plausible.

Malaria has not been studied as a possible risk factor for PAD. However, malaria may indirectly influence the pathogenesis of atherosclerosis. After repeated exposure to the malaria parasite, naturally acquired immunity can develop, resulting in chronic asymptomatic infection. This is associated with elevated inflammatory markers [12], such as C-reactive protein known to be associated with the risk of PAD [2]. Malaria is also a common cause of low birth weight which has been related to an increased risk of PAD in adulthood [13]. Recently, a causal link has been hypothesised between malaria and development of hypertension [14] known to be associated with the risk of PAD [2]. Thus, an increased prevalence of PAD might conceivably occur in malaria endemic areas.
Global Burden of Disease study [15]. Figure 1 shows the results of individual studies of PAD probability (equivalent to prevalence) and infection prevalence. Overall, we found positive associations between prevalence of PAD and country-level prevalence of HIV (log odds = 0.22, p = 0.010), tuberculosis (log odds = 0.14, p = 0.619) and malaria (log odds = 0.11, p = 0.011), although the association between PAD and tuberculosis was not statistically significant. Quantifying these associations, a 20% relative increase in infection prevalence was estimated to yield approximately 4%, 3% and 2% increases in PAD prevalence for HIV, tuberculosis and malaria, respectively. This would be roughly equivalent, for example, to an increase in almost 10 million PAD cases globally associated with HIV in 2015.

Thus, this global ecological analysis has found an association between population frequencies of HIV, tuberculosis and malaria and prevalence of PAD. Ecological analyses should not be considered conclusive, particularly as there is no assessment of possible confounding factors. Nonetheless, our results, combined with those of studies demonstrating associations between infection and risk of PAD, as well as for other CVD outcomes, indicate a need for further research at a population level on the degree of co-morbidity of HIV, tuberculosis and malaria and PAD. An important issue to be addressed would be ethnicity. Africans, for example, have a particularly high risk of PAD unexplained by traditional cardiovascular risk factors and have high rates of HIV, tuberculosis and malaria [16]. Further work investigating plausible mechanisms on how these infections might increase the risk of PAD and subsequent prevalence of PAD in LMICs, is warranted.

4 Need for Increasing Awareness of Interdependency Between Communicable and Non-communicable Disease

The possibility of the presence of endemic infection contributing to an increase in the frequency of PAD is one example of the need to consider the interdependency between communicable and non-communicable diseases. Traditionally, the prevention, control and treatment of communicable and non-communicable diseases have been approached separately at both national and local levels in HICs and LMICs. However, in recent years, the rapid increase in non-communicable diseases in LMICs, alongside the severe limitation in health care resources, has led to calls for greater integration in dealing with the two forms of disease [17]. Integration might include targeting public health interventions on populations experiencing dual morbidity. Encouragement might be given to incorporating non-communicable disease management into existing primary care systems in LMICs which tend to prioritise infection treatment and control. For example, providing simple inexpensive treatments to prevent major cardiovascular events and mortality in patients with PAD could be given priority [18]. Greater emphasis could be given to prevention overall including dealing with risk factors for both communicable and non-communicable diseases, such as smoking and diabetes mellitus, which increase the risk of both tuberculosis and PAD.

Although PAD is a common chronic atherosclerotic condition which causes loss of mobility and disability and is associated with reduced quality of life and an increased risk of major cardiovascular events and death, it is typically considered lower priority than acute cardiovascular conditions, such as myocardial infarction and stroke. However, in considering combined intervention strategies for HIV infection, tuberculosis and malaria and CVDs, the link between these infections and PAD should not be ignored and the rapid emergence of PAD in LMICs given the full attention it deserves.

5 Conclusion

In this perspective piece, we have presented evidence to support the hypothesis that endemic infections may be a risk factor for PAD and demonstrated by means of an ecological analysis that country-level prevalence of common endemic infections are associated with the prevalence of PAD. Further research is required but also health authorities need to recognise that public health policies to limit endemic infections may have additional beneficial effects in slowing the epidemiological transition in chronic diseases such as PAD.

Acknowledgements The Peripheral Arterial Disease Research Coalition (Europe) provided funds for data acquisition and analysis. This work was supported by the National Health and Medical Research Council of Australia (NHMRC) (fellowship to FJIF) and its Independent Research Institute Infrastructure Support Scheme. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. The funding sources had no role in the writing of the manuscript or the decision to submit for publication.

Author Contributions The authors comprise a multinational group studying the epidemiological transition in PAD. FJIF, PAA and FGRF: conceptualised this opinion piece. PAA: planned and undertook the analyses and figure generation with input from JCC and PS. All authors reviewed and edited the original draft and approved the final version, with oversight from FJIF and FGRF.

Availability of Data and Material Data available upon request.

Declarations

Conflict of Interest In the past three years, MMM has received research funding from Regeneron and Helixsmith and other research support
from Mars, Hershey, ReserveAge, Chromadex, and ArtAssist. VA has received payment from Bayer Healthcare, NovoNordisk, AstraZeneca, BoehringerIngelheim. Other authors declare no competing interests.

Ethical Approval Not applicable.

Consent to Participate Not applicable.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–40. https://doi.org/10.1016/S0140-6736(13)61249-0.

2. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8):e1020–30. https://doi.org/10.1016/S2214-109X(19)30255-4.

3. Roth GA, Mensah GA, Johnsson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010.

4. Budzynski J, Wisniewska J, Ciecierski M, Kedzia A. Association between bacterial infection and peripheral vascular disease: a review. Int J Angiol. 2016;25(1):3–13. https://doi.org/10.1055/s-0035-1547385.

5. Bloemenkamp DG, Mali WP, Tanis BC, Rosendaal FR, van den Bosch MA, Kemmeren JM, et al. Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women. Atherosclerosis. 2002;163(1):149–56. https://doi.org/10.1016/S0021-9150(01)00761-4.

6. Beckman JA, Duncan MS, Alcorn CW, So-Armah K, Butt AA, Goetz MB, et al. Association of human immunodeficiency virus infection and risk of peripheral artery disease. Circulation. 2018;138(3):255–65. https://doi.org/10.1161/CIRCULATIONNAHA.117.032647.

7. Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787–97. https://doi.org/10.1093/cid/ciu701.

8. Ye Y, Zeng Y, Li X, Zhang S, Fang Q, Luo L, et al. HIV infection: an independent risk factor of peripheral arterial disease. J Acquir Immune Defic Syndr. 2010;53(2):276–8. https://doi.org/10.1097/QAI0b013e3181ba1c31.

9. Desormais I, Harimenshi D, Niyongabo T, Lacroix P, Aboyans V, Preux PM. HIV clinical stages and lower extremity arterial disease among HIV infected outpatients in Burundi. Sci Rep. 2021;11(1):8296. https://doi.org/10.1038/s41598-021-87862-z.

10. Huaian MA, Henson D, Ticona E, Sterling TR, Garvy BA. Tuberculosis and cardiovascular disease: linking the epidemics. Trop Dis Travel Med Vaccines. 2015. https://doi.org/10.1186/s40794-015-0014-5.

11. Wang SH, Chien WC, Chung CH, Lin FH, Peng CK, Chian CF, et al. Tuberculosis increases the risk of peripheral arterial disease: a nationwide population-based study. Respiriology. 2017;22(8):1670–6. https://doi.org/10.1111/resp.13117.

12. de Mast Q, Brouwers J, Syafruddin D, Bousema T, Baidjoe AY, de Groot PG, et al. Is asymptomatic malaria really asymptomatic? Hematological, vascular and inflammatory effects of asymptomatic malaria parasitemia. J Infect. 2015;71(5):587–96. https://doi.org/10.1016/j.jinf.2015.08.005.

13. Smith CJ, Ryckman KK, Barnabei VM, Howard BV, Isasi CR, Sarto GE, et al. The impact of birth weight on cardiovascular disease risk in the Women’s Health Initiative. Nutr Metab Cardiovasc Dis. 2016;26(3):239–45. https://doi.org/10.1016/j.numecd.2015.10.015.

14. Etyang AO, Smeeth L, Cruickshank JK, Scott JA. The malaria-high blood pressure hypothesis. Circ Res. 2016;119(1):36–40. https://doi.org/10.1161/CIRCRESAHA.116.308763.

15. Global Burden of Disease. www.healthdata.org/gbd/data Seattle: Institute for Health Metrics and Evaluation; 2021 [cited 2021]. Available from: www.healthdata.org/gbd/data. Accessed 13 Mar 2020.

16. Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2017;14(3):156–70. https://doi.org/10.1038/nrcardio.2016.179.

17. Oni T, Unwin N. Why the communicable/non-communicable disease dichotomy is problematic for public health control strategies: implications of multimorbidity for health systems in an era of health transition. Int Health. 2015;7(6):390–9. https://doi.org/10.1093/inthealth/ihv040.

18. Fowkes FG, Forster RB, Levin CE, Naidoo NG, Roy A, Shu C, et al. Prioritization of treatments for lower extremity peripheral arterial disease: a nationwide population-based study. J Am Coll Cardiol. 2017;69(13):1837–46. https://doi.org/10.1016/j.jacc.2017.02.027.

19. The World Bank. Washington: The World Bank; [cited 2021]. Available from: https://databox.worldbank.org/world-devel opment-indicators/the-world-by-income-and-region.html. Accessed 24 Aug 2020.